Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studies daily life and feelings of people with Friedreich ataxia

Follows people with Friedreich ataxia through daily life using questionnaires and a phone app.

Plain-language title generated from the registry record
Registry title: Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia

Key facts

Where
Paris, FranceSee the site

Where in France

  • Paris Brain InstituteParis, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
German Center for Neurodegenerative Diseases (DZNE)
Trial code
NCT05943002
Record updated
1 April 2026
Original description
The PROFA study is an international, multi-centric observational and validation study to assess the patient-reported, psychosocial and economic outcomes of patients with Friedreich Ataxia (FA). Eligible patients will be recruited from six study centers in Germany, Austria and France. Patients will complete a baseline assessment via face-to-face interviews at the study centers and multiple momentary follow-up assessments via a mobile-health app at home daily to monthly for six months. Study results will gain essential and in-depth insights into the daily life of patients with FA.Read full original descriptionShow less

Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia

The PROFA study is an international, multi-centric observational and validation study to assess the patient-reported, psychosocial and economic outcomes of patients with Friedreich Ataxia (FA). Eligible patients will be recruited from six study centers in Germany, Austria and France. Patients will complete a baseline assessment via face-to-face interviews at the study centers and multiple momentary follow-up assessments via a mobile-health app at home daily to monthly for six months. Study results will gain essential and in-depth insights into the daily life of patients with FA.

Inclusion: FA confirmed by molecular genetic testing; Ataxia severity of ≤30 points according to the Scale of the Assessment and Rating of Ataxia (SARA); Access to a smartphone or tablet and able to operate the device; Older than 12 years.

Exclusion: Lack of ability to give consent; Ataxia severity >30 according to the Scale of the Assessment and Rating of Ataxia (SARA).

ClinicalTrials.gov NCT05943002